Döbrönte Z, Szepes Z, Izbéki F, Gervain J, Lakatos L, Pécsi G, Ihász M, Lakner L, Toldy E, Czakó L. Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis? World J Gastroenterol 2014; 20(29): 10151-10157 [PMID: 25110443 DOI: 10.3748/wjg.v20.i29.10151]
Corresponding Author of This Article
László Czakó, MD, PhD, 1st Department of Medicine, University of Szeged, Dugonics tér, P.O.Box: 427, 6701 Szeged, Hungary. czako.laszlo@med.u-szeged.hu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 7, 2014; 20(29): 10151-10157 Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10151
Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?
Zoltán Döbrönte, Zoltán Szepes, Ferenc Izbéki, Judit Gervain, László Lakatos, Gyula Pécsi, Miklós Ihász, Lilla Lakner, Erzsébet Toldy, László Czakó
Zoltán Döbrönte, Miklós Ihász, Lilla Lakner, Department of Gastroenterology and Internal Medicine, Markusovszky Teaching Hospital, H-9700 Szombathely, Hungary
Zoltán Szepes, László Czakó, 1st Department of Medicine, University of Szeged, 6701 Szeged, Hungary
Ferenc Izbéki, Judit Gervain, 1st Department of Internal Medicine, Szent György Regional Hospital, H-8000 Székesfehérvár, Hungary
László Lakatos, Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, H-8200 Veszprém, Hungary
Gyula Pécsi, Department of Gastroenterology, Karolina Hospital, H-9200 Mosonmagyaróvár, Hungary
Erzsébet Toldy, Central Laboratory, Markusovszky Teaching Hospital, H-9700 Szombathely, Hungary
Erzsébet Toldy, Institute of Diagnostics, Faculty of Health Sciences, University of Pécs, H-7621 Pécs, Hungary
Author contributions: Döbrönte Z and Czakó L designed the research; Döbrönte Z, Szepes Z, Izbéki F, Gervain J, Lakatos L, Pécsi G, Ihász M, Lakner L and Czakó L performed the research; Toldy E analysed the data and Döbrönte Z wrote the paper.
Supported by TÁMOP-4.2.2.A-11/1/KONV-2012-0035 and OTKA K101521
Correspondence to: László Czakó, MD, PhD, 1st Department of Medicine, University of Szeged, Dugonics tér, P.O.Box: 427, 6701 Szeged, Hungary. czako.laszlo@med.u-szeged.hu
Telephone: +36-62-545187 Fax: +36-62-545185
Received: January 12, 2014 Revised: March 12, 2014 Accepted: April 21, 2014 Published online: August 7, 2014 Processing time: 207 Days and 4 Hours
Core Tip
Core tip: Acute pancreatitis is the most common and potentially fatal complication of endoscopic retrograde cholangiopancreatography (ERCP). Non-steroidal anti-inflammatory drugs have been suggested to be effective in prospective controlled trials, but the results are inconclusive. A prospective, randomised, placebo-controlled multicentre study was therefore conducted in five endoscopic units. The results for 665 patients who randomly received a suppository containing 100 mg indomethacin or placebo before ERCP were evaluated. There was no difference between the indomethacin and placebo groups in the incidence of either post-ERCP pancreatitis or hyperamylasaemia. Rectal indomethacin is not effective in preventing post-ERCP pancreatitis in average-risk patients.
